Vaxart Inc Receivables Turnover Ratio (VXRT), from the third quarter 2026 to the third quarter 2025 current and historic results, rankings and more - CSIMarket
Vaxart Inc Accounts Receivables Turnover Ratio from the third quarter 2026 to the third quarter 2025
Quarterly Results, Trends, Rankings, Statistics
Vaxart Inc 's ability to collect its outstanding accounts receivable from its corporate clients, has improved in the third quarter 2026 to a ratio of 5.19, above the company average. This is a clear sign of healthy business climate in the Biotechnology & Pharmaceuticals industry and improving liquidity at their respective customers, during the third quarter 2026. Average receivable collection period, for the Vaxart Inc in Sep 30 2026 quarter, has decreased to 70 days, compared to 73 days, in the Jun 30 2026 quarter.
If we take a look into Healthcare sector 49 other companies have achieved higher receivables turnover ratio. While total ranking has deteriorated relative to the period ending Sep 30 2026 from 472 to 490.
Evaluation of Vaxart s Next-Generation Oral COVID-19 Vaccine: Initiation of Phase 2b Sentinel CohortVaxart Inc. has recently announced the commencement of the 400-subject sentinel cohort for its Phase 2b study, designed to scrutinize the safety, immunogenicity, and efficacy of its novel oral pill COVID-19 vaccine candidate, when juxtaposed against an approved mRNA vaccine comparator. This pivotal step underscores a significant milestone as Vaxart endeavors to introduce a groundbreaking modality for COVID-19 vaccination, expanding the horizons of vaccine administration.The primary of this sentinel portion of the Phase 2b study is to holistically evaluate the safety, immunogenicity, and efficacy of Vaxart s innovative oral pill vaccine. Initial focus will be on comprehending the immunogenic profile elicited by the oral vaccine in comparison to an established mRNA vaccine, providing a robust framework for subsequent phases of clinical assessment. Given the promising outcomes of the Phase 1 and 2a trials, the Phase 2b study is designed to further substantiate the potential of this oral vaccine in producing a comparable or superior immune response, potentially revolutionizing the approach to COVID-19 immunization.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
